[go: up one dir, main page]

AR093585A1 - COMPOSITION FOR IMMEDIATE AND PROLONGED RELEASE - Google Patents

COMPOSITION FOR IMMEDIATE AND PROLONGED RELEASE

Info

Publication number
AR093585A1
AR093585A1 ARP130104308A ARP130104308A AR093585A1 AR 093585 A1 AR093585 A1 AR 093585A1 AR P130104308 A ARP130104308 A AR P130104308A AR P130104308 A ARP130104308 A AR P130104308A AR 093585 A1 AR093585 A1 AR 093585A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
composition according
active ingredient
tolterodine
inner layer
Prior art date
Application number
ARP130104308A
Other languages
Spanish (es)
Inventor
Ahuja Varinder
Verma Rajan
Vinayakrao Barabde Umesh
Hagsten Arne
Wannerberger Kristin
Boorugu Rambabu
Vilasrao Somwanshi Amol
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR093585A1 publication Critical patent/AR093585A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende una red de matriz abierta comprendiendo un primer ingrediente farmacéuticamente activo; uno o más agentes formadores de matriz; y cuentas de liberación controlada comprendiendo un segundo ingrediente farmacéuticamente activo. Reivindicación 2: Una composición farmacéutica de acuerdo con la reivindicación 1, en donde uno o más agentes formadores de matriz se seleccionan del grupo que consiste de levadura, inulina, pululan, HPMC, maltodextrina, acacia, alginato de sodio y combinaciones de los mismos. Reivindicación 3: Una composición farmacéutica de acuerdo con la reivindicación 1 ó 2, en donde la red de matriz abierta también comprende manitol, trehalosa y/o rafinosa. Reivindicación 6: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde el primer ingrediente farmacéuticamente activo es el acetato de desmopresina. Reivindicación 7: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 6, en donde las cuentas de liberación controlada comprenden un centro (1) de un material inerte soluble en agua, insoluble en agua o engrosado en agua que tiene: (i) en el centro (1) una capa opcional interna de revestimiento de sellado (2) de un polímero sustancialmente insoluble en agua o sustancialmente soluble en agua; (ii) una capa interna que contiene droga (3) cubriendo el centro (1) o una capa interna de revestimiento de sellado (2) y conteniendo el segundo ingrediente activo; y (iii) en la capa interna que contiene droga (3) una capa de membrana externa (5) de polímero efectiva para liberación controlada del segundo ingrediente activo de la capa interna que contiene droga (3). Reivindicación 17: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 16, en donde el segundo ingrediente activo es un compuesto antimuscarínico. Reivindicación 18: Una composición farmacéutica de acuerdo con la reivindicación 17, en donde el compuesto antimuscarínico se selecciona de tolterodina, el 5- hidroximetil metabolito de tolterodina, el (S)-enantiómero de tolterodina, el 5-hidroximetil metabolito del (S)-enantiómero de tolterodina, el racemato de tolterodina, sus formas de prodroga y sales farmacológicamente aceptables de los mismos. Reivindicación 25: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 16, en donde el segundo ingrediente activo es un bloqueador alfa selectivo. Reivindicación 26: Una composición farmacéutica de acuerdo con la reivindicación 25, en donde el a-bloqueador selectivo es tamsulosina, una forma de prodroga del mismo o una sal farmacéuticamente aceptable del mismo.Claim 1: A pharmaceutical composition comprising an open matrix network comprising a first pharmaceutically active ingredient; one or more matrix forming agents; and controlled release accounts comprising a second pharmaceutically active ingredient. Claim 2: A pharmaceutical composition according to claim 1, wherein one or more matrix forming agents are selected from the group consisting of yeast, inulin, swarm, HPMC, maltodextrin, acacia, sodium alginate and combinations thereof. Claim 3: A pharmaceutical composition according to claim 1 or 2, wherein the open matrix network also comprises mannitol, trehalose and / or raffinose. Claim 6: A pharmaceutical composition according to any one of claims 1 to 5, wherein the first pharmaceutically active ingredient is desmopressin acetate. Claim 7: A pharmaceutical composition according to any one of claims 1 to 6, wherein the controlled release accounts comprise a center (1) of a water soluble, water insoluble or water thickened inert material having: (i ) in the center (1) an optional internal sealing coating layer (2) of a substantially water insoluble or substantially water soluble polymer; (ii) an inner layer containing drug (3) covering the center (1) or an inner layer of sealing lining (2) and containing the second active ingredient; and (iii) in the inner layer containing drug (3) an outer membrane layer (5) of polymer effective for controlled release of the second active ingredient from the inner layer containing drug (3). Claim 17: A pharmaceutical composition according to any one of claims 1 to 16, wherein the second active ingredient is an antimuscarinic compound. Claim 18: A pharmaceutical composition according to claim 17, wherein the antimuscarinic compound is selected from tolterodine, the 5- hydroxymethyl metabolite of tolterodine, the (S) -enantiomer of tolterodine, the 5-hydroxymethyl metabolite of (S) - tolterodine enantiomer, tolterodine racemate, its prodrug forms and pharmacologically acceptable salts thereof. Claim 25: A pharmaceutical composition according to any one of claims 1 to 16, wherein the second active ingredient is a selective alpha blocker. Claim 26: A pharmaceutical composition according to claim 25, wherein the selective α-blocker is tamsulosin, a prodrug form thereof or a pharmaceutically acceptable salt thereof.

ARP130104308A 2012-11-21 2013-11-21 COMPOSITION FOR IMMEDIATE AND PROLONGED RELEASE AR093585A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20

Publications (1)

Publication Number Publication Date
AR093585A1 true AR093585A1 (en) 2015-06-10

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104308A AR093585A1 (en) 2012-11-21 2013-11-21 COMPOSITION FOR IMMEDIATE AND PROLONGED RELEASE

Country Status (18)

Country Link
EP (1) EP2922525A1 (en)
JP (1) JP2016500088A (en)
KR (1) KR20150085826A (en)
CN (1) CN104797240A (en)
AR (1) AR093585A1 (en)
AU (1) AU2013349682A1 (en)
BR (1) BR112015011430A2 (en)
CA (1) CA2891365A1 (en)
EA (1) EA201590805A1 (en)
HK (1) HK1213779A1 (en)
IL (1) IL238648A0 (en)
IN (1) IN2015DN03984A (en)
MX (1) MX2015006399A (en)
PH (1) PH12015501096A1 (en)
SG (2) SG11201503913TA (en)
TW (1) TW201422254A (en)
WO (1) WO2014079922A1 (en)
ZA (1) ZA201503603B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814753B2 (en) 2013-07-23 2017-11-14 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
KR20150144209A (en) * 2014-06-16 2015-12-24 훼링 비.브이. Pharmaceutical composition comprising stabilized desmopressin or pharmaceutically acceptable salt thereof
MX2017006655A (en) * 2014-11-20 2018-03-12 Allergan Inc Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist.
BR112017014953A2 (en) 2015-01-12 2018-03-13 Nano Pharmaceutical Laboratories Llc controlled release microglobules in layers and methods for producing them
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR20180054655A (en) * 2015-09-01 2018-05-24 웰즐리 파마슈티컬스 엘엘씨 Prolonged, delayed and immediate release formulations
KR20180066113A (en) * 2015-09-30 2018-06-18 웰즐리 파마슈티컬스 엘엘씨 Composition for reducing urinary frequency
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (en) * 2015-11-23 2017-08-01 魏斯理製藥公司 Composition for reducing frequency of urination, method of making and use thereof
MX2018007326A (en) * 2015-12-18 2019-03-28 Wellesley Pharmaceuticals Llc Composition for reducing frequency of urination, method of making and use thereof.
EP3445343A1 (en) 2016-04-21 2019-02-27 Valcuria AB Composition and method for pretreating cancer
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN110049757A (en) * 2017-01-11 2019-07-23 辉凌公司 Quickly disintegrated pharmaceutical composition
KR20190021180A (en) * 2017-08-22 2019-03-05 아주대학교산학협력단 Pharmaceutical complex formulations for treating neurodegenerative diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003184A1 (en) 1996-07-19 1998-01-29 Clarke-Garegg, Margaret, A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (en) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2003233118B8 (en) * 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (en) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 Oral cavity quick dissolving preparation and production method thereof
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
CN102245171A (en) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 Slow-release particle and a production method therefor
AU2010277207B2 (en) * 2009-07-31 2014-06-26 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
NZ619857A (en) * 2010-03-29 2015-05-29 Ferring Bv A fast dissolving pharmaceutical composition
JO3112B1 (en) * 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
MX356601B (en) * 2010-03-30 2018-05-29 Productos Maver S A De C V Pharmaceutical combination with anti-migraine effect, in solid presentation of extended release.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
IN2015DN03984A (en) 2015-10-02
IL238648A0 (en) 2015-06-30
SG11201503913TA (en) 2015-06-29
CA2891365A1 (en) 2014-05-30
WO2014079922A1 (en) 2014-05-30
MX2015006399A (en) 2015-07-21
JP2016500088A (en) 2016-01-07
HK1213779A1 (en) 2016-07-15
EP2922525A1 (en) 2015-09-30
CN104797240A (en) 2015-07-22
BR112015011430A2 (en) 2017-07-11
SG10201703388TA (en) 2017-05-30
KR20150085826A (en) 2015-07-24
AU2013349682A1 (en) 2015-06-04
EA201590805A1 (en) 2015-11-30
PH12015501096A1 (en) 2015-07-27
TW201422254A (en) 2014-06-16
ZA201503603B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
AR093585A1 (en) COMPOSITION FOR IMMEDIATE AND PROLONGED RELEASE
PE20161373A1 (en) DELAYED RELEASE COMPOSITIONS OF LINACHLOTID
AR122580A2 (en) DOSAGE FORM OF DOXYLAMINE AND PYRIDOXINE AND/OR THEIR METABOLITES OR SALTS
AR080735A1 (en) A PHARMACEUTICAL COMPOSITION OF FAST DISSOLUTION
AR090898A1 (en) A FORMULATION OF DELAYED RELEASE PHARMACO
JP2016518337A5 (en)
AR104984A1 (en) SELECTIVE COMPOUNDS FOR PYY AND ITS USES
JP2016500088A5 (en)
BR112016017808A8 (en) compound or pharmaceutically acceptable salt, use of a compound and composition for inhibiting a beta-amyloid effect in a neuronal cell
AR088232A1 (en) PHARMACEUTICAL COMPOSITIONS
AR093705A1 (en) DEPSIPEPTIDE AND ITS USES
CL2009000598A1 (en) Oral pharmaceutical composition comprising time-controlled pulsatile release particles (tpr), containing a weakly basic poorly soluble drug and an organic acid separated by a sustained release layer, and rapid release particles (rr); capsule comprising it; and its use to treat emesis.
ES2609821T3 (en) Dry powder inhalers comprising a vehicle other than lactose and a ternary component
AR080736A1 (en) PHARMACEUTICAL COMPOSITION OF RAPID DISSOLUTION, USEFULLY DIVERSE, AND PROCESS TO PREPARE IT
PE20141539A1 (en) A NEW THERAPEUTIC COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE PRINCIPLE
RU2016136193A (en) AMINO CARBONYL CARBAMATE COMPOUNDS
CR20150297A (en) COMICRONIZATION PRODUCT THAT INCLUDES ULIPRISTAL ACETATE
AR092356A1 (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN AND METHOD OF PREPARATION OF THE FORMULATION
CL2012003341A1 (en) Pharmaceutical composition for oral administration comprising bendamustine or an ester, a salt or a solvate thereof, and an excipient which is a non-ionic and hydrophilic surfactant; pharmaceutical combination; and its use for the treatment of chronic lymphocytic leukemia and multiple myeloma, among other diseases.
CL2016002318A1 (en) Pharmaceutical composition in the form of a solution comprising a liquid carrier comprising water and between 20% and 95% of one or more alcohols and sildenafil citrate dissolved in said liquid carrier at a concentration of between 7 and 125 mg / ml; methods to obtain it; oral dosage form; oral dosage form; kits
EP2939663A4 (en) FUSION-EXTRUDED PHARMACEUTICAL COMPOSITION FOR CONTROLLING RELEASE AND ORAL ADMINISTERED MEDICINE CONTAINING THE SAME
CO6400019A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES RACETAM AND CARNITINE AND PROCESS FOR PREPARATION
PE20151300A1 (en) TOPICAL ANTIFUNGAL COMPOSITION FOR THE TREATMENT OF ONICHOMYCOSIS
FI3831385T3 (en) Mandelate salts of pirlindole enantiomers for use in medicine
MX2019000442A (en) DERIVATIVES OF ETHINYL.

Legal Events

Date Code Title Description
FB Suspension of granting procedure